Open AccessExpression of BAF57 in ovarian cancer cells and drug sensitivity
Author(s) -
Yamaguchi Takahiro,
Kurita Tomoko,
Nishio Kazuto,
Tsukada Junichi,
Hachisuga Toru,
Morimoto Yasuo,
Iwai Yoshiko,
Izumi Hiroto
Publication year - 2015
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12612
Subject(s) - gene knockdown , ovarian cancer , cisplatin , cancer research , abcg2 , paclitaxel , biology , cell cycle , cell growth , doxorubicin , transfection , cancer , microbiology and biotechnology , cell culture , gene , atp binding cassette transporter , chemotherapy , genetics , transporter , biochemistry
The SMARCE1 (SWI / SNF‐related, matrix‐associated, and actin‐dependent regulator of chromatin, subfamily e, member 1) encodes BAF57 protein. Previously, we reported that BAF 57 is a predictive marker of endometrial carcinoma. In this study, we investigated BAF 57 expression in ovarian cancer cell lines and their sensitivities to cisplatin, doxorubicin, paclitaxel, and 5‐fluorouracil. BAF 57 expression was strongly correlated with sensitivities to cisplatin, doxorubicin, and 5‐fluorouracil in 10 ovarian cancer cell lines. Paclitaxel sensitivity was also correlated with BAF 57 expression, but without significance. In A2780 ovarian cancer cells, knockdown of BAF 57 using specific si RNA increased cell cycle arrest at G 1 phase and the sensitivities to these anticancer agents. cDNA microarray analysis of A2780 cells transfected with BAF 57 si RNA showed that 134 genes were positively regulated by BAF 57, including ATP ‐binding cassette, sub‐family G ( WHITE ), member 2 ( ABCG 2 ) encoding breast cancer resistance protein ( BCRP ). We confirmed that knockdown of BAF 57 decreased BCRP expression in ovarian cancer cells by Western blot analysis, and that ABCG 2 gene expression might be regulated transcriptionally. These results suggested that BAF 57 is involved in ovarian cancer cell growth and sensitivity to anticancer agents, and that BAF 57 may be a target for ovarian cancer therapy.